GLP-1 inhibition of pancreatic islet cell apoptosis

Irina A Urusova1, Loredana Farilla, Hongxiang Hui

  • 1Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, 8723 Alden Drive, Suite 290, Los Angeles, CA 90046, USA.

Insights

Glucagon-like peptide-1 (GLP-1) exhibits antiapoptotic properties, crucial for pancreatic health and diabetes mellitus (DM) treatment. This finding holds promise for preventing DM and enhancing islet transplantation success.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Metabolic Diseases

Background:

  • Apoptosis is integral to pancreatic function, diabetes mellitus (DM) development, and islet transplantation outcomes.
  • Glucagon-like peptide-1 (GLP-1), a key incretin hormone, influences glucose metabolism and pancreatic gene expression.
  • Emerging research highlights GLP-1's significant antiapoptotic effects.

Purpose of the Study:

  • To investigate the antiapoptotic role of Glucagon-like peptide-1 (GLP-1).
  • To explore the clinical implications of GLP-1's antiapoptotic properties in diabetes mellitus and islet transplantation.
  • To assess the potential of GLP-1 in preventing and treating diabetes mellitus.

Main Methods:

  • Review of existing literature on GLP-1, apoptosis, and diabetes.
  • Analysis of GLP-1's mechanisms of action on pancreatic cells.
  • Evaluation of clinical relevance for DM treatment and islet transplantation.

Main Results:

  • Glucagon-like peptide-1 (GLP-1) demonstrates potent antiapoptotic effects.
  • These properties are relevant for managing overt diabetes mellitus.
  • GLP-1 may aid in preventing DM in impaired glucose tolerance stages and improve islet transplant success.

Conclusions:

  • The antiapoptotic function of GLP-1 presents a novel therapeutic avenue.
  • GLP-1's pleiotropic effects warrant further investigation for DM prevention and treatment.
  • GLP-1 holds significant potential for improving outcomes in metabolic and transplant medicine.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...